Walpar Nutritions Ltd
Incorporated in 2009, Walpar Nutritions Ltd manufactures and trades Pharmaceutical, Nutraceutical, Herbal and Ayurvedic commodities[1]
- Market Cap ₹ 41.6 Cr.
- Current Price ₹ 44.2
- High / Low ₹ 53.3 / 37.7
- Stock P/E 26.3
- Book Value ₹ 17.0
- Dividend Yield 0.00 %
- ROCE 17.6 %
- ROE 11.9 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company's working capital requirements have reduced from 55.2 days to 39.1 days
Cons
- Stock is trading at 2.60 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 8.07% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Dec 2020 1m | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 16.71 | 1.43 | 6.07 | 26.76 | 28.70 | 51.31 | 60.16 | 63.97 | |
| 15.50 | 1.05 | 5.61 | 25.68 | 27.92 | 49.54 | 57.32 | 61.30 | |
| Operating Profit | 1.21 | 0.38 | 0.46 | 1.08 | 0.78 | 1.77 | 2.84 | 2.67 |
| OPM % | 7.24% | 26.57% | 7.58% | 4.04% | 2.72% | 3.45% | 4.72% | 4.17% |
| 0.00 | 0.00 | 0.00 | 0.02 | 0.27 | 0.13 | 0.10 | 0.15 | |
| Interest | 0.73 | 0.05 | 0.18 | 0.48 | 0.34 | 0.21 | 0.10 | 0.06 |
| Depreciation | 0.29 | 0.02 | 0.12 | 0.28 | 0.25 | 0.21 | 0.41 | 0.47 |
| Profit before tax | 0.19 | 0.31 | 0.16 | 0.34 | 0.46 | 1.48 | 2.43 | 2.29 |
| Tax % | 36.84% | 25.81% | 6.25% | -26.47% | 34.78% | 24.32% | 30.45% | |
| 0.12 | 0.23 | 0.15 | 0.42 | 0.29 | 1.11 | 1.69 | 1.58 | |
| EPS in Rs | 0.38 | 0.22 | 0.46 | 0.32 | 1.18 | 1.80 | 1.68 | |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 29% |
| 3 Years: | 31% |
| TTM: | 26% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 70% |
| 3 Years: | 58% |
| TTM: | -20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 12% |
| 1 Year: | -9% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 8% |
| Last Year: | 12% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Dec 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1.93 | 3.00 | 3.34 | 4.54 | 4.54 | 4.70 | 9.39 | 9.39 |
| Reserves | 0.00 | 0.23 | 1.44 | 6.49 | 6.78 | 8.64 | 5.63 | 6.62 |
| 5.55 | 5.88 | 5.46 | 4.38 | 3.21 | 0.32 | 0.00 | 0.21 | |
| 5.69 | 5.44 | 5.45 | 7.95 | 7.33 | 9.84 | 15.90 | 18.85 | |
| Total Liabilities | 13.17 | 14.55 | 15.69 | 23.36 | 21.86 | 23.50 | 30.92 | 35.07 |
| 1.12 | 1.15 | 1.07 | 0.94 | 0.83 | 1.48 | 2.29 | 2.49 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.03 | 0.04 |
| Investments | 0.00 | 0.00 | 0.06 | 2.93 | 2.84 | 4.70 | 4.70 | 5.06 |
| 12.05 | 13.40 | 14.56 | 19.49 | 18.17 | 17.30 | 23.90 | 27.48 | |
| Total Assets | 13.17 | 14.55 | 15.69 | 23.36 | 21.86 | 23.50 | 30.92 | 35.07 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Dec 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| -0.76 | 0.40 | 1.38 | -0.32 | 1.09 | 3.13 | 2.71 | |
| -0.66 | 0.00 | -0.70 | -4.58 | 0.46 | -0.88 | -1.23 | |
| 1.07 | -0.24 | -0.06 | 4.27 | -1.52 | -2.18 | -0.42 | |
| Net Cash Flow | -0.35 | 0.17 | 0.62 | -0.63 | 0.03 | 0.07 | 1.06 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Dec 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 160.55 | 2,141.50 | 430.54 | 124.26 | 111.66 | 71.78 | 102.84 |
| Inventory Days | 130.73 | 1,690.75 | 369.26 | 103.22 | 89.87 | 39.99 | 32.83 |
| Days Payable | 186.46 | 2,156.44 | 434.08 | 130.02 | 99.69 | 67.10 | 93.80 |
| Cash Conversion Cycle | 104.82 | 1,675.81 | 365.73 | 97.45 | 101.84 | 44.67 | 41.87 |
| Working Capital Days | 60.07 | 1,028.64 | 268.79 | 79.79 | 79.99 | 46.31 | 39.13 |
| ROCE % | 3.84% | 6.55% | 5.34% | 11.56% | 17.64% |
Documents
Announcements
-
Outcome of Board Meeting
13 November 2025 - Unaudited H1 (30 Sep 2025) results; standalone PAT ₹99.90L, consolidated PAT ₹150.21L.
-
Integrated Filing- Financial
13 November 2025 - Unaudited standalone & consolidated H1 results (30 Sep 2025): consolidated revenue Rs 3,662.12L, profit Rs 150.21L.
-
Outcome of Board Meeting
13 November 2025 - Board approved unaudited standalone and consolidated H1 FY26 results: standalone profit Rs99.90L, consolidated profit Rs150.21L, limited review unmodified.
-
Structural Digital Database
18 October 2025 - SDD compliance certificate for quarter ended 30 Sep 2025; captured 2 events; no non-compliance (Walpar Nutritions).
-
Structural Digital Database
10 October 2025 - SDD compliance certificate for quarter ended 30 Sep 2025; captured two events; no non-compliance.
Business Overview:[1]
Company manufactures and sells Nutraceutical and Herbal dietary supplement formulations, ingredients and research. It manufactures private label brands for different companies and its own brands, selling through online and direct channels. Company is a specialized Contract manufacturer for different formulation in Nutraceuticals and Herbal products